Rajal B Shah

Dr. Rajal B Shah

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
RSRajal B Shah
Rajal B Shah
JMJeffrey S. Montgomery
Jeffrey S. Montgomery
JMJames E. Montie
James E. Montie
LKLakshmi P. Kunju
Lakshmi P. Kunju

12 September 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KRKathia E. Rodarte
Kathia E. Rodarte
SHShaked Nir Heyman
Shaked Nir Heyman
LGLei Guo
Lei Guo
LFLydia Flores
Lydia Flores
TSTrisha K. Savage
Trisha K. Savage
JJJane E. Johnson
Jane E. Johnson
Most patients with prostate adenocarcinoma develop resistance to therapies targeting the androgen receptor (AR). Consequently, a portion of these patients develop AR-independent neuroendocrine (NE) prostate cancer (NEPC), a rapidly progressing cancer with limited therapies and poor survival outcomes. Current research to understand the progression to NEPC suggests a model of lineage plasticity whereby AR-dependent luminal-like tumors progress toward an AR-independent NEPC state. Genetic analysis of human NEPC identified frequent loss of RB1 and TP53, and the loss of both genes in experimental models mediates the transition to a NE lineage. Transcriptomics studies have shown that lineage transcription factors ASCL1 and NEUROD1 are present in NEPC. In this study, we modeled the progression of prostate adenocarcinoma to NEPC by establishing prostate organoids and subsequently generating subcutaneous allograft tumors from genetically engineered mouse models harboring Cre-induced loss of Rb1 and Trp53 with Myc overexpression (RPM). These tumors were heterogeneous and displayed adenocarcinoma, squamous, and NE features. ASCL1 and NEUROD1 were expressed within NE-defined regions, with ASCL1 being predominant. Genetic loss of Ascl1 in this model did not decrease tumor incidence, growth, or metastasis; however, there was a notable decrease in NE identity and an increase in basal-like identity. This study provides an in vivo model to study progression to NEPC and establishes the requirement for ASCL1 in driving NE differentiation in prostate cancer. Significance: Modeling lineage transitions in prostate cancer and testing dependencies of lineage transcription factors have therapeutic implications, given the emergence of treatment-resistant, aggressive forms of neuroendocrine prostate cancer. See related commentary by McQuillen and Brady, p. 3499


1 May 2015 in Human Pathology
Verified
Journal Article
Closed access
RSRajal B Shah
Rajal B Shah
JBJames Bentley
James Bentley
ZJZach Jeffery
Zach Jeffery
ADAngelo M. DeMarzo
Angelo M. DeMarzo

1 January 2011 in Histopathology
Verified
Journal Article
Closed access
PDF file
JCJason C Carvalho
Jason C Carvalho
MWMatthew J Wasco
Matthew J Wasco
LKLakshmi P Kunju
Lakshmi P Kunju
DTDafydd G Thomas
Dafydd G Thomas
RSRajal B Shah
Rajal B Shah

21 May 2019 in The Prostate
Verified
Journal Article
Closed access
PDF file
RSRajal B Shah
Rajal B Shah
KSKaren T. Shore
Karen T. Shore
JYJiyoon Yoon
Jiyoon Yoon
SMSavvas Mendrinos
Savvas Mendrinos
JMJesse K. McKenney
Jesse K. McKenney
WTWei Tian
Wei Tian